Olema Pharmaceuticals Inc. (NASDAQ: OLMA) shares dropped 12.9% to $10.40 on Tuesday, driven by a widening second-quarter net loss of $63.2 million and the delay of top-line data from its pivotal Phase 3 OPERA-01 trial until the first quarter of 2027. The financial results reflected increased spending on late-stage clinical development for its lead candidate palazestrant and early-stage studies for OP-3136, causing earnings per share (EPS) of $(0.61) to miss analyst consensus estimates of $(0.55). Despite the negative market reaction, the company completed enrollment in the OPERA-01 trial and secured a collaboration with Bayer, signaling continued progress in its pipeline execution.

The widening loss was primarily driven by higher research and development (R&D) expenses, which rose to $57.8 million from $43.9 million year-over-year. This increase included higher costs for clinical activities and personnel, partially offset by a $10.0 million milestone expense recognized in the prior year. General and administrative (G&A) expenses also increased to $9.4 million from $4.0 million, reflecting investments in corporate infrastructure. The company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities.

Key Financial Metrics

The following table outlines the key earnings figures disclosed for the quarter ended June 30, 2026:

Clinical Progress and Partnerships

Olema highlighted significant operational milestones alongside its financial results. Enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer is complete. Top-line data from this trial are expected in the first quarter of 2027. Additionally, the company presented initial Phase 1 clinical data for OP-3136, a novel KAT6 inhibitor, at the 2026 ASCO Annual Meeting, showing anti-tumor activity across multiple dose levels.

A strategic development was the announcement of a clinical trial collaboration and supply agreement with Bayer. This partnership will evaluate OP-3136 in combination with darolutamide, Bayer’s androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC). Enrollment for this study is scheduled to begin in the fourth quarter of 2026.

Market Reaction and Technical Outlook

The stock’s decline pushed it significantly below key technical indicators. Olema is trading at $10.97, which is approximately 9.6% lower than its 20-day simple moving average (SMA) of $11.56. The stock is also trading 7.3% below its 50-day SMA of $11.27, indicating a bearish trend. The moving average convergence divergence (MACD) is below its signal line, suggesting momentum is fading and could lead to further declines unless the stock can reclaim that baseline.

Key technical levels include:

• Key Resistance: $11.50 — a nearby level where rebounds can stall, aligning with the 50-day SMA.
• Key Support: $9.00 — a level where buyers previously stepped in, close to the 52-week low zone.

Analyst Consensus and Ratings

Despite the recent price drop, the stock carries a Buy rating with an average price forecast of $43.00. Recent analyst actions reflect cautious optimism:

• HC Wainwright & Co.: Buy (Lowers Forecast to $36.00) (August 11)
• Guggenheim: Buy (Lowers Forecast to $35.00) (May 13)

What the Numbers Show

The divergence between the reported EPS and analyst estimates underscores the capital-intensive nature of Olema’s current development phase. While the absolute miss of $0.06 per share is modest, the 10.91% percentage deviation highlights the sensitivity of forecasts to rising R&D burn rates. The increase in non-GAAP R&D expenses to $48.9 million, excluding stock-based compensation, indicates that core operational costs are accelerating as the company advances palazestrant toward potential commercial launch. Investors will likely monitor whether the upcoming OPERA-01 data readout can justify the elevated expenditure trajectory against the backdrop of a robust $461.1 million cash position.

Olema Pharmaceuticals, Inc. granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026. The awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $12.08 per share, equal to the last reported sale price of the Company’s common stock as reported by Nasdaq on July 1, 2026.

Key Details of the Grant

The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan. Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond.